{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:42:30Z","timestamp":1782960150592,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T00:00:00Z","timestamp":1442188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T00:00:00Z","timestamp":1442188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/bmt.2015.211","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T13:43:44Z","timestamp":1442238224000},"page":"67-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A randomized study of melphalan 200\u2009mg\/m2 vs 280\u2009mg\/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT"],"prefix":"10.1038","volume":"51","author":[{"given":"W I","family":"Bensinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P S","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T A","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T R","family":"Chauncey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D G","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D J","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O W","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Ifthikharuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Vescio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G L","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,14]]},"reference":[{"key":"BFbmt2015211_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2015211_CR2","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","volume":"106","author":"J Blade","year":"2005","unstructured":"Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755\u20133759.","journal-title":"Blood"},{"key":"BFbmt2015211_CR3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt2015211_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. [erratum appears in J Clin Oncol. 2006 Jun 10;24(17):2687]. J Clin Oncol 2006; 24: 929\u2013936.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015211_CR5","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"J-P Fermand","year":"1998","unstructured":"Fermand J-P, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131\u20133136.","journal-title":"Blood"},{"key":"BFbmt2015211_CR6","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","volume":"13","author":"BL Samuels","year":"1995","unstructured":"Samuels BL, Bitran JD . High-dose intravenous melphalan: a review (Review). J Clin Oncol 1995; 13: 1786\u20131799.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015211_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200\u2009mg\/m2 melphalan and 8\u2009Gy total body irradiation plus 140\u2009mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial. Blood 2002; 99: 731\u2013735.","journal-title":"Blood"},{"key":"BFbmt2015211_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/sj.bmt.1704946","volume":"35","author":"A Spencer","year":"2005","unstructured":"Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971\u2013977.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015211_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.bmt.1703757","volume":"30","author":"C Thieblemont","year":"2002","unstructured":"Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 769\u2013775.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015211_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbmt.2004.03.001","volume":"10","author":"GL Philllips","year":"2004","unstructured":"Philllips GL, Meisenberg B, Reece DE, Adams VR, Badros A, Brunner J et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant 2004; 10: 473\u2013483.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015211_CR11","first-page":"1672","volume":"100","author":"DE Reece","year":"2002","unstructured":"Reece DE, Vesole D, Flomenberg N, Badros A, Filicko J, Herzig R et al. Intensive therapy with high-dose melphalan (MEL) 280\u2009mg\/m2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma. Blood 2002; 100: 1672.","journal-title":"Blood"},{"key":"BFbmt2015211_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BFbmt2015211_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/sj.bmt.1705384","volume":"37","author":"K Lilleby","year":"2006","unstructured":"Lilleby K, Garcia P, Gooley T, McDonnell P, Taber R, Holmberg L et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplant. Bone Marrow Transplant 2006; 37: 1031\u20131035.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015211_CR14","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood.V118.21.2040.2040","volume":"118","author":"EAJ Faber","year":"2011","unstructured":"Faber EAJ, Loberiza FR Jr ., Akhtari M, Bierman P, Bociek RG, Maness L et al. A retrospective analysis comparingBEAM versus melphalan prior to first autologous peripheral blood hematopoietic stem cell transplant in newly diagnosed multiple myeloma patients. Blood 2011; 118: 2040.","journal-title":"Blood"},{"key":"BFbmt2015211_CR15","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","volume":"95","author":"JJ Lahuerta","year":"2010","unstructured":"Lahuerta JJ, Mateos MV, Martinez-Lopez J, Grande C, de la Rubia J, Rosinol L et al. Busulfan 12\u2009mg\/kg plus melphalan 140\u2009mg\/m2 versus melphalan 200\u2009mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study. Haematologica 2010; 95: 1913\u20131920.","journal-title":"Haematologica"},{"key":"BFbmt2015211_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2141.2002.03519.x","volume":"117","author":"AD Clark","year":"2002","unstructured":"Clark AD, Douglas KW, Mitchell LD, McQuaker IG, Parker AN, Tansey PJ et al. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment. [Erratum appears in Br J Haematol 2002 Sep.118(4):1201]. Br J Haematol 2002; 117: 605\u2013612.","journal-title":"Br J Haematol"},{"key":"BFbmt2015211_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","volume":"115","author":"M Roussel","year":"2010","unstructured":"Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115: 32\u201337.","journal-title":"Blood"},{"key":"BFbmt2015211_CR18","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","volume":"16","author":"S Lonial","year":"2010","unstructured":"Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT et al. A phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 2010; 16: 5079\u20135086.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2015211_CR19","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.","journal-title":"N Engl J Med"},{"key":"BFbmt2015211_CR20","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434\u20132441.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015211_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0005-2736(79)90217-7","volume":"550","author":"DT Vistica","year":"1979","unstructured":"Vistica DT . Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. Biochim Biophys Acta 1979; 550: 309\u2013317.","journal-title":"Biochim Biophys Acta"},{"key":"BFbmt2015211_CR22","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621\u20134629.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015211_CR23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1200\/JCO.2007.13.6028","volume":"26","author":"N Blijlevens","year":"2008","unstructured":"Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy\u2014European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519\u20131525.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015211_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","volume":"38","author":"ML Grazziutti","year":"2006","unstructured":"Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006; 38: 501\u2013506.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015211","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:04:44Z","timestamp":1648058684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFbmt2015211"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.211","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,14]]},"assertion":[{"value":"8 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WB received research funding for this trial from Astra-Zeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}